Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global $9.2 Bn Chronic Lymphocytic Leukemia (7MM) Market Opportunity Analysis and Forecasts to 2027 - ResearchAndMarkets.com

May 20, 2019

DUBLIN--(BUSINESS WIRE)--May 20, 2019--

The “Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027” report has been added to ResearchAndMarkets.com’s offering.

Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens. During the forecast period, the global CLL market will welcome five new drugs-Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide).

It is estimated that the value of the CLL market in the 7MM (US, France, Germany, Italy, Spain, UK, and Canada) in 2017 was $7.7B. Among these sales, 79.5% ($6.1B) were generated in the US, with the 5EU representing the next largest region by sales, with an estimated 18.5% ($1.4B). Canada contributed the smallest proportion of sales, at 2.0% ($157M) of the global CLL market. By 2027, the US is forecast to represent a similar proportion of the 7MM sales, at 79.6%. The 5EU and Canada will account for 18.3% and 2.0% of the 7MM CLL market, respectively.

It is projected that the CLL sales will rise to $9.2B in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada) by 2027, at a modest compound annual growth rate (CAGR) of 1.8%. In particular, US CLL market is expected to grow more rapidly than the 5EU or Canada, increasing to $7.4B by 2027, at a still-modest CAGR of 1.9%. Sales in the other regions are also expected to increase by the end of the forecast period, with the 5EU and Canada having a CAGR of 1.7% and 1.8%, respectively.

This is driven by increasing incidence, driven primarily by aging populations, label expansions into the first-line setting for AbbVie/Roche’s Venclexta, frontline approval of the combination of AbbVie/Johnson & Johnson’s Imbruvica + Venclexta, and the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens. Generic and biosimilar erosion of some of the mainstays of CLL treatment is also expected during the forecast period, particularly the use of generic ibrutinib and biosimilar rituximab will lead to a decline in sales. A lack of innovative drugs in the late-stage pipeline with novel mechanisms of action means that next-generation agents are not expected to generate significant sales.

The report “Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027”, answers the following key questions

Key Topics Covered:

1 Table & Figures

2 Chronic Lymphocytic Leukemia: Executive Summary

2.1 Modest Growth in the CLL Market Expected from 2017-2027

2.2 Combinations of Targeted Drugs

2.3 Unmet Needs Exist in CLL, Particularly for Therapies of Fixed Duration as Well as More Efficacious Therapies for Patients with Adverse Prognostic Features

2.4 Commercial Opportunity for Therapies that Provide a Cure

2.5 Late-Stage Pipeline Agents to Have Low Impact on the Future CLL Treatment Landscape

2.6 What Do Physicians Think?

2.6.1 Defined Course of Treatment

2.6.2 Combination Therapies

2.6.3 Measuring Minimal Residual Disease Negativity

2.6.4 Therapies with Curative Potential

2.6.5 Chimeric Antigen Receptor-T Cell Therapy

2.6.6 PD-1/PD-L1 Checkpoint Inhibitors

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Rai and Binet Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods - Population

5.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of CLL

5.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging and Modified Rai Staging)

5.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging)

5.4.6 High-Risk Cytogenetics (11q Deletion, 13q Deletion, 17p Deletion, p53 mutation, CD38, ZAP70 and IGHV [Unmutated]) Among the Diagnosed Incident Cases of CLL

5.4.7 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of CLL

5.5 Epidemiological Forecast for CLL (2017-2027)

5.5.1 Diagnosed Incident Cases of CLL

5.5.2 Age-Specific Diagnosed Incident Cases of CLL

5.5.3 Sex-Specific Diagnosed Incident Cases of CLL

5.5.4 Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis

5.5.6 Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis

5.5.7 Diagnosed Incident Cases of CLL by High-Risk Cytogenetics

5.5.8 Diagnosed Prevalent Cases of CLL

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Treatment Algorithms

6.2.1 Young and Fit Patients (Without 17p Deletion/p53 Mutation)

6.2.2 Elderly and Fit or Young and Unfit Patients (Without 17p Deletion/p53 Mutation)

6.2.3 Elderly and Frail Patients (Without 17p Deletion/p53 Mutation)

6.2.4 Patients with High-Risk 17p Deletion and/or p53 Mutation

6.3 Marketed Therapies

6.3.1 Anti-CD20 Monoclonal Antibodies

6.3.2 Subcutaneous Rituxan

6.3.3 BCR Inhibitors

6.3.4 BCL-2 Inhibitor

6.4 Preferred Treatments Within the Seven Major Markets

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Unmet Need and Opportunity: Efficacious Therapies for High-Risk 17p Deletion Patients

7.3 Unmet Need and Opportunity: Therapies That Are of a Limited, Definite Duration of Treatment

7.4 Unmet Need and Opportunity: More Efficacious Treatment Options in First-Line Therapy for Elderly and Frail, or Young and Fit Patients

7.5 Unmet Need and Opportunity: Prognostic Markers That Determine the Optimal Treatment Strategy

7.6 Unmet Need and Opportunity: Identification of Patients Who Could Benefit from Early Treatment

8 R&D Strategies

8.1 Overview

8.1.1 Targeting the High-Risk 17p Deletion Population

8.1.2 Targeting Other B-Cell Receptor Proteins

8.1.3 Combination Therapies

8.2 Clinical Trials Design

8.2.1 Ongoing Late-Stage Clinical Trials of Marketed and Pipeline Drugs

8.2.2 Evaluating CLL Clinical Trial Endpoints

8.2.3 Selecting Suitable Comparator Arms

9 Pipeline Assessment

9.1 Overview

9.1.1 Umbralisib and Ublituximab

9.1.2 Calquence and Zanubrutinib

9.1.3 Revlimid

9.2 Innovative Early-Stage Approaches

9.2.1 PD-1/PD-L1 Checkpoint Inhibitors

9.2.2 Chimeric Antigen Receptor T Cell Therapy

9.2.3 Other Innovative Approaches

9.3 Summary of Products in Development for CLL

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Canada

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic/Biosimilar Erosion

11.3.9 Pricing of Pipeline Agents

11.4 Primary Research - Key Opinion Leaders Interviewed for This Report

11.4.1 KOLs

11.5 Primary Research - Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Managing Analyst

11.6.3 Therapy Area Directors

11.6.4 Epidemiologist

11.6.5 Epidemiologist Reviewers

11.6.6 Global Director of Therapy Analysis and Epidemiology

11.6.7 Global Head and EVP of Healthcare Operations and Strategy

11.7 About

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/384ex1

View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005351/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematology



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/20/2019 06:58 AM/DISC: 05/20/2019 06:58 AM


All contents © copyright 2019 The Associated Press. All rights reserved.